Answers are grounded in this paper and cite their sources.
This review highlights current and emerging therapies for juvenile idiopathic arthritis, suggesting the need for personalized approaches.
Despite substantial therapeutic progress, achieving sustained, drug-free remission remains a challenge for many JIA patients. Precision medicine - guided by predictive biomarkers, pharmacovigilance data, and real-world evidence - is essential for optimizing individualized care. Future efforts should prioritize the development of safer, more tolerable, and accessible therapies tailored to the unique needs of pediatric populations.
No takes yet. Share an insight, caveat, or question.
Konte et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: